NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
(Total Views: 219)
Posted On: 09/17/2019 4:16:25 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Human CBD Study Results Published in Peer Reviewed Clinical Journal
Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced the publication of final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented DehydraTECH(TM) powered TurboCBD(TM); capsules. According to the update results were published in the peer reviewed medical journal, Advances in Therapy, which focuses on clinical medicine and pharmaceutical research and has been published continually since 1984. Lexaria reported several key findings highlighted in the publication, including but not limited to: CBD in-plasma levels with the 90mg dose of TurboCBD were significantly higher than with the generic 90 mg dose at both 90 and 120 minutes; and only the 90 mg dose of TurboCBD was elevated (i.e., greater than the placebo) at 30 minutes and remained elevated at 4 hours.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announced the publication of final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented DehydraTECH(TM) powered TurboCBD(TM); capsules. According to the update results were published in the peer reviewed medical journal, Advances in Therapy, which focuses on clinical medicine and pharmaceutical research and has been published continually since 1984. Lexaria reported several key findings highlighted in the publication, including but not limited to: CBD in-plasma levels with the 90mg dose of TurboCBD were significantly higher than with the generic 90 mg dose at both 90 and 120 minutes; and only the 90 mg dose of TurboCBD was elevated (i.e., greater than the placebo) at 30 minutes and remained elevated at 4 hours.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼